Development of a Novel High-Throughput Screening Platform for BK Channel Modulato
Development of a Novel High-Throughput Screening Platform for BK Channel Modulato
批准号:
8478440
负责人:
FRANK T HORRIGAN
金额:
$35.48万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2016-05-31
关键词:
Adverse effectsAffectAnimal ModelAsthmaBiological AssayBrainCalciumCellsChronic Obstructive Airway DiseaseClinical TrialsComplexData SetDevelopmentDiabetes MellitusDiseaseDrug TargetingElectrophysiology (science)EngineeringEpilepsyEpithelial CellsErectile dysfunctionExhibitsGlaucomaGoalsHealthHumanHypertensionIntestinesIonsIrritable Bowel SyndromeLifeMalignant Bone NeoplasmMalignant neoplasm of brainMembraneMethodsMiningMolecular BankMuscle CellsMutationMyocardial IschemiaNeuronsOrganOveractive BladderPainPancreatitisParalysedPharmaceutical ChemistryPharmaceutical PreparationsPhysiologicalPhysiologyPlayPoint MutationPotassiumPotassium ChannelProcessPropertyProstateProteinsPsychotic DisordersRegulationResearchResourcesRestRheumatoid ArthritisRoleSecretory CellSignal TransductionSpecificityStomachStrokeStructure-Activity RelationshipSystemTestingThalliumTherapeuticTimeTissuesTraumatic Brain InjuryUnited States National Institutes of HealthUrinary IncontinenceVariantbasebody systembonedesigndrug developmenthigh throughput screeningimprovedinhibitor/antagonistinnovationlarge-conductance calcium-activated potassium channelsmutantnovelnovel strategiespatch clampprogramspublic health relevancescreeningsensorsmall moleculesmall molecule librariestherapeutic targettoolvoltage
中文摘要
描述(由申请人提供):钾传导BK通道是治疗多种人类疾病的有吸引力的药物靶点。大量研究表明,BK通道遍布全身,在多种生理和疾病过程中发挥重要作用。抑制或增强BK通道功能的化合物(调节剂)已被测试或建议用于治疗中风、癫痫、精神病、疼痛、创伤性脑损伤、低钾性周期性麻痹、哮喘、慢性阻塞性肺病、心绞痛、动脉高血压、缺血性心脏病、勃起功能障碍、尿失禁、胃动力亢进、肠易激综合征、胰腺炎、癌症(脑、骨和前列腺)、类风湿关节炎、青光眼和糖尿病。然而,这种多样化的治疗潜力在很大程度上仍未得到开发。现有的BK通道调节剂尚未经过临床试验,效力和组织特异性较差。我们的长期目标是开发有效的组织特异性人类BK通道调节剂。这些化合物在非靶组织中几乎不会产生不良反应,因此可以作为有效的治疗药物以及研究选定器官中BK通道功能的重要研究工具。我们之前的研究和初步结果表明,BK通道调制器表现出多种作用机制,这限制了传统高通量筛选识别有用调制器的能力。因此,本提案的目标是开发和验证一种创新的高通量筛选系统,能够检测和评估通过不同作用机制起作用的小分子调节剂的效力,并对不同组织中表达的BK通道变体具有选择性。该筛选包括突变BK通道的新使用,旨在提高检测的灵敏度,以选择具有所需特性的调节剂。拟议的筛选将克服发现和开发有效的组织特异性BK通道调节剂的几个关键障碍;并且适合筛选数十万种化合物。
英文摘要
DESCRIPTION (provided by applicant): Potassium-conducting BK channels are attractive drug targets for the treatment of a wide variety of human disorders. Significant studies have shown that BK channels are distributed throughout the body and play important roles in a variety of physiological and disease processes. Compounds that inhibit or enhance BK channel function (modulators) have been tested or proposed to treat stroke, epilepsy, psychoses, pain, traumatic brain injury, hypokaleamic periodic paralysis, asthma, COPD, angina, arterial hypertension, ischemic heart disease, erectile dysfunction, urinary incontinence, gastric hypermotility, irritable bowel syndrome, pancreatitis, cancer (brain, bone, and prostate), rheumatoid arthritis, glaucoma and diabetes. However this diverse therapeutic potential remains largely untapped. Existing BK channel modulators have not advanced beyond clinical trials and suffer from poor potency and tissue specificity. Our long-term goal is to develop potent tissue-specific modulators of human BK channels. Such compounds should induce little to no adverse effects in non-target tissue, and therefore could serve as effective therapeutics as well as important research tools for the study of BK channel function in selected organs. Our previous research and preliminary results suggest that BK channel modulators exhibit diverse mechanisms of action which limit the ability of conventional high throughput screens to identify useful modulators. Therefore, the goal of this proposal is to develop and validate an innovative high throughput screening system, capable of detecting and evaluating the potency of small molecule modulators that act by different mechanisms of action and are selective for BK channel variants expressed in different tissues. The screen includes the novel use of mutant BK channels, engineered to increase the sensitivity of the assay to select modulators with the desired properties. The proposed screen will overcome several key barriers in the discovery and development of potent, tissue-specific BK channel modulators; and be suitable for screening hundreds of thousands of compounds.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Novel High-Throughput Screening Platform for BK Channel Modulato
-
批准号:8847742
-
项目类别:
-
资助金额:$26.09万
-
财政年份:2013
-
负责人:FRANK T HORRIGAN
-
依托单位:
Development of a Novel High-Throughput Screening Platform for BK Channel Modulato
-
批准号:8666659
-
项目类别:
-
资助金额:$29.78万
-
财政年份:2013
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:7263688
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:7363624
-
项目类别:
-
资助金额:$9.25万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:7588897
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:7736248
-
项目类别:
-
资助金额:$25.21万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of Ca-activated K channel gating
-
批准号:6647153
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:8045488
-
项目类别:
-
资助金额:$32.91万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of Ca-activated K channel gating
-
批准号:6529755
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of Ca activated K channel gating
-
批准号:6430801
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of Ca-activated K channel gating
-
批准号:6785385
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
Allosteric mechanisms of CA-activated K channel gating
-
批准号:7892986
-
项目类别:
-
资助金额:$33.24万
-
财政年份:2001
-
负责人:FRANK T HORRIGAN
-
依托单位:
海外基金